Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$344.61B | 23.7x | 1.48 | HK$111.30 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.3% Upside | Upgrade to Pro+ | |
BeOne Medicines HK | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$282.39B | -199.9x | -3.1 | HK$199.90 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$162.39B | 36.6x | 0.52 | HK$40 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9.6% Downside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$122.79B | -124.1x | 12.2 | HK$135.70 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$116.17B | -150.3x | 0.54 | HK$508 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.3% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$66.82B | 44.2x | -1.53 | HK$27.34 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.8% Downside | Upgrade to Pro+ | |
TransThera Sciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$64.50B | -217.7x | 3.77 | HK$159.80 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$61.28B | -45.2x | -1.71 | HK$107 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -31.7% Downside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$56.65B | 175.9x | -2.21 | HK$47.06 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.5% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$34.52B | -266.6x | 0.59 | HK$15.88 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.9% Upside | Upgrade to Pro+ | |
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$34.09B | -117.2x | -2.61 | HK$17.70 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$30.70B | 94.8x | 0.72 | HK$24.24 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.1% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$26.79B | -19.5x | 0.12 | HK$74.50 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25% Upside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$20.86B | -68.1x | -1.15 | HK$71 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
MiRXES Holding | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$16.56B | -10.7x | HK$59.75 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.55B | 35.8x | 0.22 | HK$12.66 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -44.8% Downside | Upgrade to Pro+ | |
Nanjing Leads Biolabs | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.49B | -31.3x | HK$64.10 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$11.77B | 71.8x | 0.08 | HK$17.23 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16% Upside | Upgrade to Pro+ | |
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$11.36B | -27.7x | 0.19 | HK$7.81 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$11.14B | 75.3x | 0.49 | HK$29.50 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -56.9% Downside | Upgrade to Pro+ | |
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$10.80B | -19x | -0.85 | HK$19.36 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.46B | -152.5x | -1.92 | HK$9.15 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -42.2% Downside | Upgrade to Pro+ | |
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.69B | -31.4x | -0.57 | HK$29.48 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.97B | -19.1x | -0.42 | HK$15.82 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.46B | -13.7x | -0.63 | HK$11.15 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.40B | -16x | -0.33 | HK$6.16 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -51.3% Downside | Upgrade to Pro+ | |
Medtide | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.34B | 37.1x | 0.48 | HK$30.66 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.2% Upside | Upgrade to Pro+ | |
Visen Pharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.30B | -20.1x | -0.85 | HK$41.66 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cloudbreak Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.04B | -3.8x | HK$4.73 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.96B | 3.4x | 0.01 | HK$4 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.8% Upside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.56B | -5.2x | 0.27 | HK$7.49 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.05B | -78.8x | -1.31 | HK$0.73 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.82B | -2.9x | 1.33 | HK$2.26 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.64B | 92.5x | -2.56 | HK$1.25 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.7% Downside | Upgrade to Pro+ | |
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.37B | -10.1x | -0.36 | HK$4.35 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.27B | -4.8x | -0.13 | HK$4.02 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.04B | 67.1x | 0.64 | HK$3.94 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioDlink International | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.76B | 215.8x | -11.22 | HK$2.26 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.62B | -2.7x | -1.36 | HK$4.14 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.7% Upside | Upgrade to Pro+ | |
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.57B | -8.1x | -0.18 | HK$14.51 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.40B | -3.5x | 0.09 | HK$1.93 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.6% Upside | Upgrade to Pro+ | |
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.22B | -13.1x | -0.26 | HK$7.94 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.22B | -13.8x | -0.24 | HK$6.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.14B | -5.2x | -0.08 | HK$2.48 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$184.14M | -13x | -0.14 | HK$0.19 | 12.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laekna | Hong Kong | Healthcare | Biotechnology & Medical Research | -1.06 | HK$12.82 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |